CN114246911A - 一种治疗脑血栓的中药组合物及其制备方法 - Google Patents
一种治疗脑血栓的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN114246911A CN114246911A CN202111004443.4A CN202111004443A CN114246911A CN 114246911 A CN114246911 A CN 114246911A CN 202111004443 A CN202111004443 A CN 202111004443A CN 114246911 A CN114246911 A CN 114246911A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- cerebral thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 206010008132 Cerebral thrombosis Diseases 0.000 title claims abstract description 28
- 201000001429 Intracranial Thrombosis Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 20
- 241000258920 Chilopoda Species 0.000 claims abstract description 19
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 18
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 16
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 14
- 241000488974 Loranthus Species 0.000 claims abstract description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 13
- 241001643642 Viticis Species 0.000 claims abstract description 13
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 230000003071 parasitic effect Effects 0.000 claims abstract description 13
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 10
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 3
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- 241000522620 Scorpio Species 0.000 claims abstract description 3
- 239000009490 scorpio Substances 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- 239000000843 powder Substances 0.000 claims description 33
- 241000239226 Scorpiones Species 0.000 claims description 17
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 11
- 241001061264 Astragalus Species 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 210000004233 talus Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000005325 percolation Methods 0.000 claims description 7
- 241000405414 Rehmannia Species 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- 241000212322 Levisticum officinale Species 0.000 claims description 3
- 239000001645 levisticum officinale Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 description 53
- 239000008280 blood Substances 0.000 description 53
- 241000700159 Rattus Species 0.000 description 19
- 230000017531 blood circulation Effects 0.000 description 14
- 241001092040 Crataegus Species 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 241000125175 Angelica Species 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 241000736199 Paeonia Species 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 7
- 230000036461 convulsion Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 230000008081 blood perfusion Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 240000007218 Ipomoea hederacea Species 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Insects & Arthropods (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗脑血栓的中药组合物及其制备方法,属于医药技术领域。本发明公开的一种治疗脑血栓的中药组合物,按重量份数计,含有以下组分:生黄芪25‑35份、当归25‑35份、赤芍10‑20份、川芎10‑20份、三七10‑20份、全蝎5‑15份、蜈蚣8‑15份、生地10‑20份、党参25‑35份、天麻10‑20份、桑寄生10‑20份、生山楂25‑35份、蔓荆子5‑10份。该中药组合物在治疗或预防脑血栓方面具有显著效果,药物副作用低,具有很好的临床推广价值。
Description
技术领域
本发明为医药技术领域,具体涉及一种治疗脑血栓的中药组合物及其制备方法。
背景技术
脑血栓又称缺血性脑中风,是一种常见的脑血管疾病,主要是由于脑动脉粥样硬化,血管内膜损伤使脑动脉管腔狭窄,进而因多种因素使局部血栓形成,使动脉狭窄加重或完全闭塞,导致脑组织缺血、缺氧、坏死,引起神经功能障碍的一种脑血管病。由于血栓产生的血管部位的不同和面积的不同,会导致脑血栓患者出现头晕、口眼歪斜、肢体功能障碍、语言不清或失语等一些症状甚至于死亡。西药作用靶点单一,西医要针对每种病变使用溶栓、神经保护、消炎、营养等多种药物联合使用,费用高昂。并且多数西药,包括阿司匹林都有不同程度的副作用,而绝大多数西药的副作用明显,对胃肠、肝肾造成不同程度的损伤。在治疗脑缺血、脑血栓疾病方面,中药具有长效性强,安全无毒的优点,非常适合中老年脑血栓疾病患者服用。由于中药可以多方面地同时发挥作用,其在临床上已展现了非常好的疗效,且中药制作费用低廉。不足的是,目前治疗脑血栓疾病的中药品种有限,因此,需要继续开发有效的制备脑血栓疾病的中药制剂,满足广大患者的需要。目前西医对脑血栓的治疗,多采用扩张血管剂、降压药和抗血小板凝聚剂、活血化瘀芳香开窍降脂抗凝类等药物,如阿司匹林、西洛他唑片、华林林纳片等,但只能缓解症状,不能根治,并且具有一定副作用,因而增加了治疗难度,在使用上存在一定的弊端。现有技术中合成药物治标不治本,且容易损伤胃肠道粘膜,药物毒副作用大,而中药则存在疗效不确定,缺少相应药物制剂。
因此,提供一种治疗脑血栓的中药组合物是本领域技术人员亟需解决的问题。
发明内容
本发明的目的在于提供一种治疗脑血栓的中药组合物,以解决合成药物治标不治本,毒副作用大等问题。
为了实现上述目的,本发明采用如下技术方案:
一种治疗脑血栓的中药组合物,所述中药组合物按重量份数计,含有以下组分:生黄芪25-35份、当归25-35份、赤芍10-20份、川芎10-20份、三七10-20份、全蝎5-15份、蜈蚣8-15份、生地10-20份、党参25-35份、天麻10-20份、桑寄生10-20份、生山楂25-35份、蔓荆子5-10份。
进一步的,所述中药组合物按重量份数计,含有以下组分:生黄芪30份、当归30份、赤芍15份、川芎15份、三七15份、全蝎10份、蜈蚣10份、生地15份、党参30份、天麻15份、桑寄生15份、生山楂30份、蔓荆子10份。
进一步的,所述中药组合物可以是散剂,丸剂,片剂或胶囊剂。
进一步的,所述中药组合物的制备方法包括以下步骤:
步骤1):分别取所述重量份数的三七、全蝎、蜈蚣、天麻,分别打碎研磨制成微粉,过100目筛,备用;
步骤2):取所述重量份数的生黄芪、当归、赤芍、川芎、生地、党参、桑寄生、生山楂、蔓荆子,混合后打碎研磨制成粗粉,采用渗漉法提纯,将提纯液浓缩,得药物浸膏,备用;
步骤3):将步骤1)所述微粉与步骤2)所述药物浸膏混合,即可得到所述中药组合物。
进一步的,所述步骤2)加入粗粉总重0.8倍的体积浓度为70%的乙醇溶液进行所述渗漉法提纯。
生黄芪有补气固表、通脉络、利尿、托毒排脓、生肌的功能。
当归头能破血,身能养血,尾能行血。若全用,在参、芷皆能补血;在牵牛、大黄,皆能破血,佐使定分,用者当知。从桂、附、茱萸则热;从大黄、芒硝则寒。惟酒蒸当归,又治头痛,以其诸头痛皆属木,故以血药主之。
赤芍能清热凉血;活血祛瘀。木芍药色赤,赤者主破散,主通利,专入肝家血分,故主邪气腹痛。其主除血痹、破坚积者,血瘀则发寒热,行血则寒热自止,血痹疝瘢皆血凝滞而成,肢凝滞之血,则痹和而疝瘢自消。凉肝故通顺血脉,肝主血,入肝行血,故散恶血,逐贼血。营气不和则逆于肉里,结为痈肿,行血凉血,则痈肿自消。
川芎性辛温香燥,走而不守,既能行散,上行可达巅顶;又入血分,下行可达血海。活血祛瘀作用广泛,适宜瘀血阻滞各种病症;祛风止痛,效用甚佳,可治头风头痛、风湿痹痛等症。昔人谓川萼为血中之气药,殆言其寓辛散、解郁、通达、止痛等功能。本品辛温升散,凡阴虚阳亢及肝阳上亢者不宜应用;月经过多、孕妇亦忌用。
三七具有化瘀止血,活血定痛的功效。《本草纲目》记载,止血散血定痛,金刃箭伤、跌扑杖疮、血出不止者,嚼烂涂,或为末掺之,其血即止。亦主吐血衄血,下血血痢,崩中经水不止,产后恶血不下,血运血痛,赤目痈肿,虎咬蛇伤诸病。
生地能清热凉血,养阴,生津。用于热病舌绛烦渴,阴虚内热,骨蒸劳热,内热消渴,吐血,衄血,发斑发疹。
党参味甘,性平。有补中益气、止渴、健脾益肺,养血生津。用于脾肺气虚,食少倦怠,咳嗽虚喘,气血不足,面色萎黄,心悸气短,津伤口渴,内热消渴。能治懒言短气、四肢无力、食欲不佳、气虚、气津两虚、气血双亏以及血虚萎黄等症。
天麻能息风止痉;平肝阳;祛风通络。主急慢惊风;抽搐拘挛;眩晕;头痛;半身不遂;肢麻;风湿痹痛。治眩晕眼黑,头风头痛,肢体麻木,半身不遂,语言蹇涩,小儿惊痫动风。《本草新编》记载,天麻,能止昏眩,疗风去湿,治筋骨拘挛瘫痪,通血脉,开窍,余皆不足尽信。
桑寄生有祛风湿,补肝肾,强筋骨,安胎元的作用。《本草求真》记载,桑寄生,号为补肾补血要剂。缘肾主骨,发主血,苦入肾肾得补,则筋骨有力。甘补血,血得补则发受其灌荫而不枯脱落矣。故凡内而腰痛、筋骨笃疾、胎堕,外而金疮、肌肤风湿,何一不借此以为主治乎。
生山楂能开胃消食、化滞消积、活血散瘀、化痰行气。临床研究证实,山楂能显著降低血清胆固醇及甘油三酯,有效防治动脉粥样硬化。
蔓荆子用于外感头痛,偏正头风,昏晕目暗,赤眼多泪,目睛内痛,齿龈肿痛,湿痹拘挛。《本草纲目》记载,蔓荆实,气轻味辛,体轻而浮,上行而散,故所主者皆头面风虚之症。
本方证由脑血栓后,正气亏虚,阴虚血瘀,脉络瘀阻所致。本方证以气阴两虚为本,血瘀为标,治以补气养阴为主,兼以活血祛瘀通络。
本方重用生黄芪,补益元气,气旺则血行,瘀去络通,为君药。当归活血通络,为臣药。赤芍、川芎、三七助当归以活血祛瘀,且三七止血而不留瘀,活血而不破血。全蝎、蜈蚣相须为用,息风止痉,通络散结之功增强,然二药为辛燥伤阴之品,合用生地、党参,可滋阴、益气,亦可防因燥伤阴之弊,亦为佐药。天麻平抑肝阳,祛风通络。桑寄生有“通调血脉”之功。生山楂活血消积,能扩张血管,降低血压、血脂。蔓荆子,气轻味辛,体轻而浮,上行而散,故引诸药上行至头,为引经药。诸药合同,共奏补气活血,通脉舒络之功。
本发明的有益效果如下:
1.本发明选用的天然的动物、植物药为原料,各组分符合药政法规定,利用各味中药的综合作用进行脑血栓康复的治疗,对于脑血栓引起的半身不遂,肢体僵硬挛缩,舌强语謇,口眼歪斜,智力减退,精神意识障碍等症,具有非常好的康复效果。
2.本发明活血化瘀,通经活络,醒神开窍。
3.本发明采用纯天然的动物、植物组成,药性温和,无毒副作用和不良反应,适合脑血栓预防及患病后的康复治疗。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种治疗脑血栓的中药组合物,中药组合物按重量份数计,含有以下组分:生黄芪25g、当归25g、赤芍10g、川芎10g、三七10g、全蝎5g、蜈蚣8g、生地10g、党参25g、天麻10g、桑寄生10g、生山楂25g、蔓荆子5g。
中药组合物的制备方法包括以下步骤:
步骤1):分别取重量份数的三七、全蝎、蜈蚣、天麻,分别打碎研磨制成微粉,过100目筛,备用;
步骤2):取重量份数的生黄芪、当归、赤芍、川芎、生地、党参、桑寄生、生山楂、蔓荆子,混合后打碎研磨制成粗粉,加入粗粉总重0.8倍的体积浓度为70%的乙醇溶液,采用渗漉法提纯,将提纯液浓缩,得药物浸膏8.5g,备用;
步骤3):将步骤1)微粉与步骤2)药物浸膏混合,即可得到中药组合物。
实施例2
一种治疗脑血栓的中药组合物,中药组合物按重量份数计,含有以下组分:生黄芪30g、当归30g、赤芍15g、川芎15g、三七15g、全蝎10g、蜈蚣10g、生地15g、党参30g、天麻15g、桑寄生15g、生山楂30g、蔓荆子10g。
中药组合物的制备方法包括以下步骤:
步骤1):分别取重量份数的三七、全蝎、蜈蚣、天麻,分别打碎研磨制成微粉,过100目筛,备用;
步骤2):取重量份数的生黄芪、当归、赤芍、川芎、生地、党参、桑寄生、生山楂、蔓荆子,混合后打碎研磨制成粗粉,加入粗粉总重0.8倍的体积浓度为70%的乙醇溶液,采用渗漉法提纯,将提纯液浓缩,得药物浸膏10.2g,备用;
步骤3):将步骤1)微粉与步骤2)药物浸膏混合,即可得到中药组合物。
实施例3
一种治疗脑血栓的中药组合物,中药组合物按重量份数计,含有以下组分:生黄芪35g、当归35g、赤芍20g、川芎20g、三七20g、全蝎15g、蜈蚣15g、生地20g、党参35g、天麻20g、桑寄生20g、生山楂35g、蔓荆子8g。
中药组合物的制备方法包括以下步骤:
步骤1):分别取重量份数的三七、全蝎、蜈蚣、天麻,分别打碎研磨制成微粉,过100目筛,备用;
步骤2):取重量份数的生黄芪、当归、赤芍、川芎、生地、党参、桑寄生、生山楂、蔓荆子,混合后打碎研磨制成粗粉,加入粗粉总重0.8倍的体积浓度为70%的乙醇溶液,采用渗漉法提纯,将提纯液浓缩,得药物浸膏12g,备用;
步骤3):将步骤1)微粉与步骤2)药物浸膏混合,即可得到中药组合物。
药理学实验
1.本发明中药组合物对大鼠血瘀模型的改善作用
取健康雄性SD大鼠36只,利用随机数字表法将36只大鼠随机分为正常组、模型组、阳性对照组、实施例1组、实施例2组、实施例3组,每组6只。
为模型组、阳性对照组、实施例1组、实施例2组、实施例3组构建大鼠大脑中动脉血栓模型:取质量浓度10%的水合氯醛给SD大鼠腹腔注射进行麻醉,剂量为350mg/kg,麻醉后使大鼠右侧卧位于实验台上,在大鼠自左眼眦和外耳道连线中点处剪一长约1.5cm的切口,暴露颞前窝及鳞状骨大部,然后在颧弓和鳞状骨前联合的前下方约2mm处钻孔,开一直径约2mm的颅窗,暴露大脑中动脉,并用一小片塑料薄膜保护血管周围组织。随后将蘸有质量浓度50%的三氯化铁(用0.1mol/LHCL配置)溶液(约10μL)的大小为2mm×2mm的小片滤纸敷在该段大脑中动脉上20分钟,再用生理盐水冲洗局部组织,逐层缝合。
给药:正常组与模型组大鼠不做处理;阳性对照组大鼠每日灌胃给药阿司匹林,剂量为0.2g/kg;实施例1组大鼠每日灌胃给药本申请实施例1制备的中药组合物,剂量为1g/kg;实施例2组大鼠每日灌胃给药本申请实施例2制备的中药组合物,剂量为1g/kg;实施例3组大鼠每日灌胃给药本申请实施例3制备的中药组合物,剂量为1g/kg。
各组大鼠连续灌胃给药共计20d,于第19天给药1h后,皮下注射肾上腺素,注射剂量为0.8mg/kg;给药2h后于5℃冰水中冰浴15min。第20天给药2h后测量大鼠血流灌注量与行为学观察。
表1 大鼠血流灌注量与行为学观察(Longa评分)
组别 | 治疗前血流灌注量 | 治疗后血流灌注量 | 治疗前Longa评分 | 治疗后Longa评分 |
正常组 | 57.32±3.56 | 57.48±2.48 | 0.1±0.11 | 0.1±0.11 |
模型组 | 21.37±1.59 | 21.46±2.47 | 2.74±1.45 | 2.71±1.74 |
阳性对照组 | 21.46±3.15 | 37.87±2.45 | 2.61±1.04 | 1.78±0.35 |
实施例1组 | 21.59±2.04 | 42.61±3.65* | 2.25±1.25 | 0.98±0.26* |
实施例2组 | 21.23±2.97 | 51.43±4.21* | 2.58±1.42 | 0.4±0.12* |
实施例3组 | 22.05±1.89 | 48.53±2.58* | 2.63±1.33 | 0.62±0.69* |
注:治疗20天后与阳性对照组比较,*P<0.05;
结果显示:50%FeCl3贴敷后,脑血流迅速下降,20分钟下降至22%,脑血栓闭塞模型制作成功。与模型组比较,本发明药物可显著提高脑血流量(P<0.05),改善脑缺血后神经运动功能(P<0.05),阿司匹林组亦有效,但改善效果不如本发明中药组合物。
测量大鼠血流灌注量与行为学观察后对各组大鼠取血4ml,分装于肝素抗凝管中,全血加入质量浓度3.2%枸橼酸钠溶液(血液与抗凝剂体积比为9∶1)抗凝,并测定血液流变学参数。
表2 大鼠血液流变学参数
注:治疗20天后与模型组比较,*P<0.05;与正常对照组相比,#P<0.05.
结果显示,模型组与正常对照组比较,全血低切指数、红细胞聚集指数、卡松粘度和血浆黏度均有显著增高(P<0.05)。与模型组比较,本发明中药组合显著降低了全血低切指数、红细胞聚集指数、卡松粘度和血浆黏度(P<0.05),同样条件下,阳性对照组也降低了全血低切指数、红细胞聚集指数、卡松粘度和血浆黏度,但改善效果不如本发明中药组合物。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (5)
1.一种治疗脑血栓的中药组合物,其特征在于,所述中药组合物按重量份数计,含有以下组分:生黄芪25-35份、当归25-35份、赤芍10-20份、川芎10-20份、三七10-20份、全蝎5-15份、蜈蚣8-15份、生地10-20份、党参25-35份、天麻10-20份、桑寄生10-20份、生山楂25-35份、蔓荆子5-10份。
2.根据权利要求1所述的一种治疗脑血栓的中药组合物,其特征在于,所述中药组合物按重量份数计,含有以下组分:生黄芪30份、当归30份、赤芍15份、川芎15份、三七15份、全蝎10份、蜈蚣10份、生地15份、党参30份、天麻15份、桑寄生15份、生山楂30份、蔓荆子10份。
3.根据权利要求1或2所述的一种治疗脑血栓的中药组合物,其特征在于,所述中药组合物为散剂、丸剂、片剂或胶囊剂。
4.权利要求1或2所述的一种治疗脑血栓的中药组合物的制备方法,其特征在于,包括以下步骤:
步骤1):分别取所述重量份数的三七、全蝎、蜈蚣、天麻,分别打碎研磨制成微粉,过100目筛,备用;
步骤2):取所述重量份数的生黄芪、当归、赤芍、川芎、生地、党参、桑寄生、生山楂、蔓荆子,混合后打碎研磨制成粗粉,采用渗漉法提纯,将提纯液浓缩,得药物浸膏,备用;
步骤3):将步骤1)所述微粉与步骤2)所述药物浸膏混合,得到所述中药组合物。
5.根据权利要求4所述的制备方法,其特征在于,所述步骤2)加入所述粗粉总重0.8倍的体积浓度为70%的乙醇溶液进行所述渗漉法提纯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111004443.4A CN114246911A (zh) | 2021-08-30 | 2021-08-30 | 一种治疗脑血栓的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111004443.4A CN114246911A (zh) | 2021-08-30 | 2021-08-30 | 一种治疗脑血栓的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114246911A true CN114246911A (zh) | 2022-03-29 |
Family
ID=80791354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111004443.4A Pending CN114246911A (zh) | 2021-08-30 | 2021-08-30 | 一种治疗脑血栓的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114246911A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618455A (zh) * | 2004-09-03 | 2005-05-25 | 朱智文 | 脑血栓丸及其配方 |
CN104138424A (zh) * | 2014-08-15 | 2014-11-12 | 刘秋莲 | 一种中药组合物及其制备方法和制药用途 |
-
2021
- 2021-08-30 CN CN202111004443.4A patent/CN114246911A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618455A (zh) * | 2004-09-03 | 2005-05-25 | 朱智文 | 脑血栓丸及其配方 |
CN104138424A (zh) * | 2014-08-15 | 2014-11-12 | 刘秋莲 | 一种中药组合物及其制备方法和制药用途 |
Non-Patent Citations (1)
Title |
---|
涂春林: "益气熄风化栓汤治疗脑血栓42例临床观察", 《实用中西医结合临床》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103330780B (zh) | 一种治疗下肢静脉曲张的药物及其制备方法 | |
CN103520607A (zh) | 一种治疗胃炎的中药制剂 | |
CN104689066A (zh) | 一种用于治疗烧伤的中药组合物及其制备方法 | |
CN104173773A (zh) | 偏头痛祛风活血制剂及制备方法 | |
CN104043054A (zh) | 一种治疗中风后遗症的药物 | |
CN104587220A (zh) | 一种治疗面瘫的中药 | |
CN105687587A (zh) | 温经通络止痛膏 | |
CN104491220A (zh) | 一种治疗带状疱疹的中药组合物 | |
CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
CN105687788A (zh) | 一种软化血管的药物组合物及其应用 | |
CN105311492A (zh) | 一种用于冠状动脉粥样硬化性心脏病的药物 | |
CN103816352B (zh) | 一种治疗阴道炎的中药制剂及制备方法 | |
CN106361932A (zh) | 一种用于跌打损伤的外擦中药酊剂 | |
CN114246911A (zh) | 一种治疗脑血栓的中药组合物及其制备方法 | |
CN101647981B (zh) | 一种治疗血虚风燥型牛皮癣的药物 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN105250685A (zh) | 一种用于治疗烧伤的中药组合物及其制备方法 | |
CN104013836A (zh) | 一种治疗脑中风后遗症的中药组合物 | |
CN104338052A (zh) | 治疗脑血栓的中药配方 | |
CN103705639A (zh) | 一种治疗脑积水的中药制剂 | |
CN103751624B (zh) | 一种治疗中风后肢体麻木的药物及制备方法 | |
CN103041036B (zh) | 一种用于治疗三叉神经痛的丸剂 | |
CN104721630A (zh) | 一种用于麻醉催醒的中药制剂及制备方法 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN105362944A (zh) | 一种治疗骨科扭挫伤的中药膏剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220329 |